drugset
drugset / Trial / NCT00048503

Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older

NCT00048503 ↗

Phase 2 Completed 88 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if giving tipifarnib after standard treatment will prevent leukemia from coming back (relapsing). Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI). It blocks proteins that make leukemia cells grow.

Timeline

Start
2002-06
Primary completion
—
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule 300 mg Oral

Indications

acute myeloid leukemia